TransMedics Group, Inc.
No SEC Form 4 filings for $TMDX in the last 30 days.
TransMedics Group, Inc. director Edward M. Basile received an equity grant of 2,922 restricted stock units (RSUs) at no cash cost. This grant increased his direct holdings to 5,788 shares of the company's common stock. The transaction, reported in a Form 4 SEC filing, represents a form of equity compensation rather than a cash purchase or open-market transaction.
TransMedics Group, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including the election of eight directors, the non-binding advisory compensation for named executive officers, and an amendment to the 2019 Stock Incentive Plan. Additionally, PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. These decisions reflect shareholder support for the company's governance and compensation strategies.
TransMedics Group, Inc. (TMDX) has received an average "Moderate Buy" rating from twelve brokerages, with an average 12-month target price of $135.00, despite several recent target reductions and downgrades. The company's Q1 results showed a significant miss on EPS and contracting margins, leading to some analyst skepticism and a stock selloff. Insider selling has occurred, while institutional investors hold the vast majority of the stock.
